Health AI startup Cercle debuts with backing from Sheryl Sandberg

Health AI startup Cercle debuts with backing from Sheryl Sandberg


Sheryl Sandberg, former COO of Facebook, at Vanity Fair’s 6th Annual New Establishment Summit.

Matt Winkelmeyer | Getty Images

A new health tech startup called Cercle launched Wednesday and announced major global partners and investors, including Meta‘s former COO Sheryl Sandberg.

Cercle uses artificial intelligence to try and advance women’s health, particularly within fertility care. The company’s platform organizes unstructured medical data, such as medical records and test results, into a standardized format for fertility doctors and researchers, in the hopes it will help clinicians develop more personalized treatment plans and accelerate new discoveries in pharmaceuticals.

For instance, if a patient wants to freeze her eggs, her doctor can use Cercle’s platform to look at data from similar patients who have also had their eggs frozen. The information is de-identified and anonymous, according to Cercle, but the physician can see what kind of treatments helped or didn’t, then use that information to develop a more personalized plan of action.

“That’s the founding mission behind Cercle, to personalize and contextualize biomedical and genomics information so women can make better, more informed health decisions,” Cercle CEO and co-founder Juan Carlos Riveiro said in a release Wednesday.

Cercle’s lead investors include Sandberg and her husband Tom Bernthal through their new venture fund, Sandberg Bernthal Venture Partners, Cercle announced. Sandberg left her role as COO of Meta in June of 2022, and her fund will be “investing, supporting and scaling alongside great entrepreneurs,” according to its LinkedIn page.

Cercle is also partnering with the genetics company Eurofins Genoma, as well as US Fertility, the nation’s largest fertility network that supports more than 100 clinics.

Cercle said it will initially focus on fertility care but plans to expand to other areas within women’s health.



Source

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More
Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More